The SARM1 targeting therapeutics market is projected to grow at a CAGR of 102.1%, during the period 2033-2040

SARM1 inhibitors, having demonstrated the ability to prevent axonal degeneration, are being evaluated for the treatment of a number of neurodegenerative disorders. Once approved, these therapies are likely to capture a significant market share

Roots Analysis has announced the addition of “SARM1 Inhibitors Therapeutics Market, 2022 – 2040” report to its list of offerings.

 

Presently, several industry and non-industry stakeholders are evaluating SARM1 inhibitors as potential therapeutic agents for the treatment of neurological disorders across various preclinical studies and early stages of clinical development, worldwide. With the ongoing pace of innovation in this field, increasing RD activity and promising pre-clinical data, several promising leads are anticipated to be commercially launched over the coming decade and SARM1 targeting therapeutics market is anticipated to witness substantial growth in the mid to long-term.

 

Key Market Insights

 

Presently, several SARM1 targeting therapy candidates are being developed by various industry players

About 65% of the pipeline candidates are currently being evaluated in the preclinical stages of development, followed by those currently in the discovery stage (35%). Further, it is worth mentioning that close to 85% of the SARM1 inhibitors are small molecules.

 

Currently, a number of companies claim to be engaged in the development of SARM1 inhibitors

The SARM1 inhibitors market is dominated by the presence of large companies (81%), followed by small players (19%). In addition, around 20% of the players were established post-2010.

 

120+ articles related to SARM1 inhibitors have been published between 2011 and 2022

Majority (81%) of the articles published in this domain were research papers, followed by review papers (12%). It is important to note that more than 70% of the total number of articles were published post-2018.

 

Over 30 grants have been awarded for research related to SARM1 inhibitors, since 2014

Close to 40% of the total amount was awarded under the R01 mechanism (which supports research projects). Further, genetics and neurology emerged as the key research departments, having received 34% of the total grants, each.

 

70+ patents related to SARM1 targeting therapeutics have been filed / granted till 2022

Over the years, the number of patents filed for SARM1 inhibitors has increased gradually; majority of the patents have been filed / granted in 2021. Most of the patents in this domain are patent applications (96%), followed by granted patents (3%).

 

North America is anticipated to capture more than 65% share of the market, by 2040

By 2040, the market revenues are likely to be driven by the sales of small molecules (95%) being developed as SARM1 inhibitors. Further, sales of therapeutics targeting multiple sclerosis are likely to contribute to a majority share (~40%) of revenues, in the long term.

 

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/sarm1-inhibitors-market/request-sample.html

 

Key Questions Answered

  • Who are the leading players engaged in the development of SARM1 targeting therapeutics?
  • What is the evolving trend of publications focused on SARM1 targeting therapeutics?
  • How is the intellectual property landscape in this field likely to evolve in the foreseen future?
  • What are the recent developments and strategic initiatives undertaken by players engaged in this market space related to the research and development of SARM1 targeting therapeutics?
  • What are the key value drivers that are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

 

The financial opportunity within the SARM1 targeting therapeutics market has been analyzed across the following segments:

 

  • Type of Molecule
  • Small Molecules
  • Biologics

 

  • Target Indication
  • Multiple Sclerosis
  • Peripheral, Central and Ocular Nervous System Disorders
  • Peripheral Neuropathies
  • Glaucoma
  • Amyotrophic Lateral Sclerosis

 

  • Drug Developers
  • Company 1
  • Company 2
  • Company 3

 

  • Drug Candidates
  • Drug Candidate 1
  • Drug Candidate 2
  • Drug Candidate 3
  • Drug Candidate 4
  • Drug Candidate 5
  • Drug Candidate 6

 

  • Key Geographies 
  • North America
  • Europe

 

The research includes detailed profiles of key players (listed below); featuring an overview of the company, financial information (if available), details related to its product portfolio, patent portfolio, recent developments (including partnerships and collaborations) and an informed future outlook.

  • Disarm Therapeutics
  • Nura Bio
  • Washington University

 

For additional details, please visit 

https://www.rootsanalysis.com/reports/sarm1-inhibitors-market.html

or email sales@rootsanalysis.com

 

You may also be interested in the following titles:

  1. RNAi Market: Therapeutics and Technologies (Focus on siRNA, miRNA, shRNA and DNA) (3rd Edition): Industry Trends and Global Forecasts, 2022-2035
  2. Global Therapeutic Vaccines Market: Industry Trends and Global Forecasts, 2022-2035

 

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

 

Contact:

Ben Johnson

+1 (415) 800 3415

Ben.johnson@rootsanalysis.com


berry_cristan

44 Blog posts

Comments